Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Alterity Therapeutics Limited PRNAF OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
48/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Alterity Therapeutics Limited (PRNAF) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

PRNAF Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to Alterity Therapeutics Limited in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$518.58
-1.22%
 TGTX
TGTX
TG Therapeutics, Inc.
$34.60
+0.12%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.45
-0.20%
 NVAX
NVAX
Novavax, Inc.
$8.69
+3.58%
 OCGN
OCGN
Ocugen, Inc.
$1.95
+8.33%
 GLSI
GLSI
Greenwich LifeSciences, Inc.
$25.91
-0.42%
 NWBO
NWBO
Northwest Biotherapeutics, Inc.
$0.20
-0.50%
 GRCL
GRCL
Gracell Biotechnologies Inc.
$10.25
+0.05%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message